<table>
<thead>
<tr>
<th>ID</th>
<th>Project Title</th>
<th>Collaboration Partners</th>
<th>Disease</th>
<th>Intervention</th>
<th>Stage</th>
<th>Awarded Amount ($)</th>
<th>Continuing</th>
</tr>
</thead>
</table>
| G2017-203 | Preliminary development and phase I activities on a selected aminopyrazole compound for visceral leishmaniasis | 1. DNDi  
| G2017-211 | Process Development and Clinical Manufacturing of an Immuno-focused, Mosquito-based Pan-malaria transmission blocking vaccine: AnAPN1 v. 2.0. | 1. University of Florida  
2. CellFree Sciences Co. Ltd.  
3. Ongny Bioservices Inc.  
4. Hamamatsu Pharma Research (HPR)  
5. Infectious Disease Research Institute (IDRI)  
2. Eisai Co. Ltd.  
3. Colorado State University  
4. The University of Chicago  
5. TB Alliance                                                                                                           | Tuberculosis     | Drug                               | Lead Optimization | ¥200,332,434 | $1,867,031 | New       |
| H2017-101 | HTL for selective Plasmodium protopsome inhibitors as new potent resistance-reversing antimalarials | 1. Medicines for Malaria Venture (MMV)  
2. The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute  
| H2017-102 | New Hit-to-Lead Activity for New Anti-Malaria drugs between MMV and Sumitomo | 1. Medicines for Malaria Venture (MMV)  
2. Sumitomo Danippon Pharma Co., Ltd. (Sumitomo)                                                                                           | Malaria          | Drug                               | Hit-to-Lead        | ¥44,550,000  | $415,191  | S2014-211 |
| H2017-103 | Neglected Tropical Diseases Drug Discovery Booster III | 1. DNDi – Drugs for Neglected Diseases initiative  
2. Eisai Co. Ltd.  
4. Takeda Pharmaceutical Company Ltd  
5. Astellas Pharma Inc.                                                                                                           | Chagas disease, VL | Drug                               | Hit-to-Lead        | ¥149,832,868 | $1,396,392 | H2016-203 |
| S2017-221 | Chagas disease and Leishmaniasis Screening between DNDi and Daichi Sankyo Novare | 1. DNDi  
2. Daichi Sankyo RD Novare Co., Ltd.                                                                                                                   | Chagas disease, VL | Drug                               | Hit Identification | ¥11,900,000  | $110,904  | New       |
| T2017-272 | Novel diagnostics for schistosomiasis control: development of defined antigens for detection of Schistosoma infection-specific antibodies in blood and urine | 1. Lygature  
2. Institute of Tropical Medicine, Nagasaki University (NUTIM)  
3. Department of Parasitology, Leiden University Medical Center (LUMC)                                                                   | Schistosomiasis   | Diagnostics                         | Concept Development | ¥76,389,000  | $711,920  | New       |
| T2017-274 | Identification of Vaccine Targets that Will Block the Interaction of Plasmodium falciparum Malaria Parasites with a Complement Regulator | 1. The Pennsylvania State University  
2. Institute of Tropical Medicine, Nagasaki University  
3. Antigen Discovery, Inc.                                                                                                        | Malaria          | Vaccine                            | Antigen Identification | $88,190,035 | $821,902  | New       |
| T2017-278 | Target determination and exploratory research for discovery of new drugs against Chagas disease | 1. Nagasaki University (NKKEN)  
2. National Institute of Advanced Industrial Science and Technology (AIST)  
3. High Energy Accelerator Research Organization (KEK)  
4. London School of Hygiene and Tropical Medicine (LSHTM)                                                                 | Chagas Disease   | Drug                               | Target Identification | ¥88,235,010  | $822,321  | New       |

*All amounts are listed at the exchange rate of USD1 = JPY107.3, the approximate exchange rate on February 28, 2018.*